author-photo

Shu Jin

Takeda Pharmaceutical Company

3

Papers

41

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (35)
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)